Two groups of deacetylase enzyme have currently been identified; histone deacetylases and the Sir2 (silent information regulator)-like family of NAD-dependent deacetylases. Both families are highly conserved and have fundamental roles in transcriptional regulation. There has been great interest in targeting these enzymes as a possible treatment for cancer.
Deacetylase Target Files
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.